238 related articles for article (PubMed ID: 24216048)
1. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
Fauci JM; Sabbatino F; Wang Y; Londoño-Joshi AI; Straughn JM; Landen CN; Ferrone S; Buchsbaum DJ
Gynecol Oncol; 2014 Jan; 132(1):203-10. PubMed ID: 24216048
[TBL] [Abstract][Full Text] [Related]
2. B7-H3-targeted
Kasten BB; Arend RC; Katre AA; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
Nucl Med Biol; 2017 Apr; 47():23-30. PubMed ID: 28104527
[TBL] [Abstract][Full Text] [Related]
3. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 targeted antibody-based immunotherapy of malignant diseases.
Michelakos T; Kontos F; Barakat O; Maggs L; Schwab JH; Ferrone CR; Ferrone S
Expert Opin Biol Ther; 2021 May; 21(5):587-602. PubMed ID: 33301369
[No Abstract] [Full Text] [Related]
5. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
[TBL] [Abstract][Full Text] [Related]
6. MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
Deng M; Wu D; Zhang Y; Jin Z; Miao J
Gynecol Oncol; 2021 Jul; 162(1):190-199. PubMed ID: 33875234
[TBL] [Abstract][Full Text] [Related]
7. A novel monoclonal antibody against mouse B7-H3 developed in rats.
Yan R; Yang S; Sun J; Chen X; Zhang G; Feng P; Zhang X
Hybridoma (Larchmt); 2012 Aug; 31(4):267-71. PubMed ID: 22894780
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
9. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract][Full Text] [Related]
11. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
12. Anti-B7-H3 monoclonal antibody ameliorates the damage of acute experimental pancreatitis by attenuating the inflammatory response.
Zhuang X; Shen J; Jia Z; Wu A; Xu T; Shi Y; Xu C
Int Immunopharmacol; 2016 Jun; 35():1-6. PubMed ID: 27003113
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of tumor-expressed B7-H3 augments anti-tumor efficacy of anti-PD-L1 monotherapy rather than the combined chemoimmunotherapy in ovarian cancer.
Huang M; Luo J; Ji X; Hu M; Xue Y; Liu Q
Pharmacol Res; 2022 Dec; 186():106512. PubMed ID: 36272639
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of anti-B7-H3 antibody in an ovalbumin-induced mouse asthma model.
Chen ZR; Zhang GB; Wang YQ; Yan YD; Zhou WF; Zhu C; Chen Y; Wang J; Ji W
Ann Allergy Asthma Immunol; 2013 Oct; 111(4):276-81. PubMed ID: 24054363
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
16. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.
Yu ZH; Liu T; Zhao YH; Huang YY; Gao YT
Tumour Biol; 2014 May; 35(5):4637-44. PubMed ID: 24408020
[TBL] [Abstract][Full Text] [Related]
18. Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.
Ahmed M; Cheng M; Zhao Q; Goldgur Y; Cheal SM; Guo HF; Larson SM; Cheung NK
J Biol Chem; 2015 Dec; 290(50):30018-29. PubMed ID: 26487718
[TBL] [Abstract][Full Text] [Related]
19. [B7-H3 monoclonal antibody attenuates the inflammation and tissue injury in mice with cerulein-induced acute pancreatitis].
Zhuang X; Xu C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):323-7. PubMed ID: 26927550
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale CRISPR-Cas9 screen reveals novel regulators of B7-H3 in tumor cells.
Zhao S; Wang Y; Yang N; Mu M; Wu Z; Li H; Tang X; Zhong K; Zhang Z; Huang C; Cao T; Zheng M; Wang G; Nie C; Yang H; Guo G; Zhou L; Zheng X; Tong A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
